logo

Asia-Pacific Diabetes Care Drugs Market Size (2024 - 2029)

The Asia-Pacific diabetes drug market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes, particularly type 2, due to factors such as aging populations, sedentary lifestyles, and high alcohol and smoking rates. The region's market size is influenced by the production activities of antidiabetic drug companies, although high drug costs pose a significant challenge. Despite these challenges, the market is expected to expand, reflecting the growing demand for diabetes care solutions in the region.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research APAC Diabetes Drugs Industry Market Size

Market Size of Asia-Pacific Diabetes Care Drugs Industry

Asia-Pacific Diabetes Care Drugs Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 24.99 Billion
Market Size (2029) USD 28.70 Billion
CAGR (2024 - 2029) 2.81 %
Market Concentration Low

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Asia-Pacific Diabetes Care Drugs Market Analysis

The Asia-Pacific Diabetes Care Drugs Market size is estimated at USD 24.99 billion in 2024, and is expected to reach USD 28.70 billion by 2029, growing at a CAGR of 2.81% during the forecast period (2024-2029).

Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population. The Asia -Pacific is anticipated to experience considerable growth due to a more geriatric population and rising prevalence of diabetes mainly due to the enhanced stress level, sedentary lifestyles, smoking, and excessive consumption of alcohol that elevates the body's sugar levels have led to the growth of the market. 

Moreover, the production basis of certain antidiabetic drug companies in the region also boosted the market growth. However, the increasingly high cost of drugs is considered one of the major restraining factors for the market. According to the OECD iLibrary in Asia-Pacific, about 227 million people live with type 2 diabetes and about half of them are undiagnosed and unaware of developing long-term complications. 

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Asia-Pacific Diabetes Care Drugs Industry Segmentation

Diabetes drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Asia-Pacific diabetes care drugs market is segmented into drugs, by Route of Administration and geography. The report offers the value (in USD) and volume (in ml) for the above segments. 

Oral Anti-diabetic Drugs
Biguanides
Metformin
Alpha - Glucosidase Inhibitors
Alpha - Glucosidase Inhibitors
Dopamine -D2 Receptor Agonist
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
By Route of Administration
Oral
Subcutaneous
Intravenous
Geography
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
South Korea
Thailand
Vietnam
Rest of Asia-Pacific
Need A Different Region Or Segment?
Customize Now

Asia-Pacific Diabetes Care Drugs Market Size Summary

The Asia-Pacific diabetes care drugs market is poised for significant growth, driven by an increasing prevalence of diabetes, particularly type 2, across the region. This surge is attributed to factors such as an aging population, sedentary lifestyles, and lifestyle choices like smoking and excessive alcohol consumption, which elevate sugar levels. The market benefits from the presence of major antidiabetic drug manufacturers in the region, although high drug costs pose a challenge. Oral anti-diabetic drugs dominate the market due to their efficacy, safety, and cost-effectiveness, making them a preferred choice for managing type 2 diabetes. The introduction of new-generation oral drugs, such as DPP-4 and SGLT-2 inhibitors, has further enhanced their appeal by reducing cardiovascular risks and improving patient adherence to treatment.

China stands out as a key player in the Asia-Pacific diabetes drug market, with a substantial share and a growing number of generic drug manufacturers. The country faces challenges like slow economic growth and an aging population but continues to see a rising preference for oral anti-diabetics among patients. Initiatives like the National Essential Medicine System and reimbursement policies aim to alleviate the financial burden on diabetic patients, supporting market expansion. The market is characterized by fragmentation, with both global and regional players competing for market share. Recent mergers and acquisitions have strengthened the presence of key manufacturers, fostering innovation and market growth.

Explore More

Asia-Pacific Diabetes Care Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic Drugs

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha - Glucosidase Inhibitors

        1. 2.1.2.1 Alpha - Glucosidase Inhibitors

      3. 2.1.3 Dopamine -D2 Receptor Agonist

        1. 2.1.3.1 Bromocriptin (Cycloset)

      4. 2.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

        1. 2.1.5.1 Januvia (Sitagliptin)

        2. 2.1.5.2 Onglyza (Saxagliptin)

        3. 2.1.5.3 Tradjenta (Linagliptin)

        4. 2.1.5.4 Vipidia/Nesina (Alogliptin)

        5. 2.1.5.5 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

    2. 2.2 Insulins

      1. 2.2.1 Basal or Long Acting Insulins

        1. 2.2.1.1 Lantus (Insulin Glargine)

        2. 2.2.1.2 Levemir (Insulin Detemir)

        3. 2.2.1.3 Toujeo (Insulin Glargine)

        4. 2.2.1.4 Tresiba (Insulin Degludec)

        5. 2.2.1.5 Basaglar (Insulin Glargine)

      2. 2.2.2 Bolus or Fast Acting Insulins

        1. 2.2.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.2.2.2 Humalog (Insulin Lispro)

        3. 2.2.2.3 Apidra (Insulin Glulisine)

      3. 2.2.3 Traditional Human Insulins

        1. 2.2.3.1 Novolin/Actrapid/Insulatard

        2. 2.2.3.2 Humulin

        3. 2.2.3.3 Insuman

      4. 2.2.4 Biosimilar Insulins

        1. 2.2.4.1 Insulin Glargine Biosimilars

        2. 2.2.4.2 Human Insulin Biosimilars

    3. 2.3 Combination drugs

      1. 2.3.1 Insulin combinations

        1. 2.3.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.3.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 2.3.2 Oral Combinations

        1. 2.3.2.1 Janumet (Sitagliptin and Metformin)

    4. 2.4 Non-Insulin Injectable drugs

      1. 2.4.1 GLP-1 receptor agonists

        1. 2.4.1.1 Victoza (Liraglutide)

        2. 2.4.1.2 Byetta (Exenatide)

        3. 2.4.1.3 Bydureon (Exenatide)

        4. 2.4.1.4 Trulicity (Dulaglutide)

        5. 2.4.1.5 Lyxumia (Lixisenatide)

      2. 2.4.2 Amylin Analogue

        1. 2.4.2.1 Symlin (Pramlintide)

    5. 2.5 By Route of Administration

      1. 2.5.1 Oral

      2. 2.5.2 Subcutaneous

      3. 2.5.3 Intravenous

    6. 2.6 Geography

      1. 2.6.1 Australia

      2. 2.6.2 China

      3. 2.6.3 India

      4. 2.6.4 Indonesia

      5. 2.6.5 Japan

      6. 2.6.6 Malaysia

      7. 2.6.7 Philippines

      8. 2.6.8 South Korea

      9. 2.6.9 Thailand

      10. 2.6.10 Vietnam

      11. 2.6.11 Rest of Asia-Pacific

Asia-Pacific Diabetes Care Drugs Market Size FAQs

The Asia-Pacific Diabetes Care Drugs Market size is expected to reach USD 24.99 billion in 2024 and grow at a CAGR of 2.81% to reach USD 28.70 billion by 2029.

In 2024, the Asia-Pacific Diabetes Care Drugs Market size is expected to reach USD 24.99 billion.

Asia-Pacific Diabetes Care Drugs Market Report Snapshots

APAC Diabetes Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)